ZURICH (dpa-AFX) - The major Swiss bank UBS has downgraded Carl Zeiss Meditec from "Buy" to "Neutral" and lowered its price target from 125 to 71 euros. The medical technology company's order intake remains weak, as the recent profit warning showed, analyst Graham Doyle wrote in his review published on Monday. In addition, it is difficult to predict when an improvement will occur and a return to "normal" high single-digit sales growth will be possible. According to Doyle, the opportunities and risks are currently in balance./ag/edh

Publication of the original study: 21.06.2024 / 15:28 / GMT

First dissemination of the original study: 24.06.2024 / time not specified in study / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------